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httcense.Abstract Background and Objectives: Malignant pleural effusion is a common complication of
primary and metastatic pleural malignancies. It is usually managed by drainage and pleurodesis,
but there is no consensus as to the best method of pleurodesis, this study was designed to compare
the effectiveness, side effects, and cost of different chemical pleurodesis agents used in patients with
malignant pleural effusion.
Methods: Seventy-ﬁve patients with malignant pleural effusion were assigned into ﬁve groups
each of 15 patients, Talc slurry 5 gm, Tetracycline500 mg, Bleomycin1 IU/kg, Iodopovidone
(2%) and patients underwent tube drainage only. Tube thoracotomy was performed in all patients
and agents were administered through the chest tubes.
Results: Tetracycline, talc slurry, iodopovidone andbleomycin, resulted inan insigniﬁcantly dif-
ferent success rates of 80%, 80%, 66.6%.73.3%, at 30 days and, 66.6%, 73.3%, 60%, 66.6%, at
60 days respectively while tube alone was much lower, 40% and 26.7% respectively. Chest tubes
were removed after an average of 7.2 ± 1.4 days for tetracycline, 7 ± 0.8 days for talc slurry,
7.6 ± 0.9 days for iodopovidone and 6.4 ± 1.5 days for bleomycin which did not differ signiﬁ-
cantly. Chest pain was more common in the tetracycline group, dyspnea was more common in
the talc group, and fever was more common in the iodopovidone group.
Conclusion: Since tetracycline, talc slurry, iodopovidone, andbleomycin achieved comparable
success rates in this study, we suggest that the drug availability and cost are important factors in
choosing a sclerosing agent in developing countries.
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Although the real incidence of malignant pleural effusion is not
established, it is one of the most common problems that pulmo-
nologists and oncologists face in their daily practice [1]. In one
autopsy series metastatic pleural involvement was found in
29% of 191 cases of malignancy, but pleural effusion was pres-
ent in only slightly more than half of these cases. Therefore, theis. Production and hosting by Elsevier B.V.
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malignancy in this particular series was 15% [2]. About 75%
of malignant pleural effusions are secondary to malignancies
of the lungs, breast or lymphoma [1]. In the United States more
than 150,000 new cases of malignant pleural effusion are esti-
mated to occur each year, with 75% being due to lung or breast
cancers [3].The presence of a malignant pleural effusion indi-
cates that the patient has advanced disease with an ominous
prognosis, and with a very small chance of long-term survival.
Many patients with malignant pleural effusion have dyspnea
which limits the quality of their life. Tube thoracostomy with
bedside pleurodesis has become the most common approach
to palliate symptoms related to the effusion [1]. Pleurodesis is
the obliteration of the pleural space by fusion of the visceral
and parietal pleurae with ﬁbrous tissue. Recurrent symptom-
atic pleural effusions and pneumothoraces are indications for
pleurodesis. Most of the agents used for pleurodesis injure
the pleura and cause an inﬂammatory reaction together with
a pleural effusion. Subsequently, the local activation of the
coagulation system and the production of ﬁbrogenic cytokines
such as transforming growth factor ß lead to the production of
collagen that can result in a pleurodesis.[4].
Tetracycline, doxycycline, bleomycin, and talc have been
the agents most commonly used to produce pleurodesis [5]
.Tetracycline has been replaced by doxycycline because the for-
mer is no longer available for parenteral use in most countries.
Talc can be administered as either poudrage during thoracos-
copy or as slurry via tube thoracostomy, with similar success
rates [6]. Talc slurry is less expensive when the cost of the tho-
racoscopic procedure is considered [7].
The aim of this study was to compare the efﬁcacy of tetra-
cycline, talc slurry, Iodopovidone, bleomycin, and chest tube
alone in producing pleurodesis in patients with malignant pleu-
ral effusions.
Patients and methods
The study protocol was approved by chest department, faculty
and university councils including the Institutional Review
Board at Zagazig University Hospitals. The study was per-
formed in the chest, cardiothoracic surgery, oncology and
radiotherapy departments between June2003 and September
2005. Initially, 125 patients were enrolled in the study. How-
ever, we encountered great difﬁculty in getting follow-up for
all patients because many patients did not return for their vis-
its, did not have telephones and lived a long way from the hos-
pital. Accordingly, we continued the study until we had 60 day
follow-up in 15 patients in each group. The patients with
malignant pleural effusion met the following inclusion criteria.
1. Malignancy as proven by positive pleural ﬂuid cytology,
needle biopsy of the pleura or thoracoscopic biopsy.
2. A pleural effusion which was massive (occupying more
than three quarters of the hemithorax or extending
beyond the second rib anteriorly in the PA chest radio-
graph) or rapidly reaccumulating (dyspnea necessitating
thoracenteses every 3 days or less).
3. Subjective improvement of patient’s dyspnea following
thoracocentesis.
4. Total re expansion of the lung after ﬂuid drainage.
5. Pleural ﬂuid pH > 7.2.The following were exclusion criteria:
1. Atelectasis due to endobronchial obstruction.
2. Pleural ﬂuid pH < 7.2
3. Prior intrapleural therapy
4. Any radiotherapy to the affected hemithorax.
All patients included in the study signed an informed con-
sent which was approved by the Institutional Review Board,
after which a new chest Xray was obtained and a diagnostic
thoracentesis was performed to conﬁrm that the patient still
met the inclusion criteria.
The following investigations were done for pleural ﬂuids:
- Pleural ﬂuid glucose, protein concentration, LDH (the
upper limit of normal for serum was 480 IU/L, using
the Dimension RXL Machine:
DADE Behring.DIAMOND DIAGNOSTICS Holliston,
MA, USA.
- Pleural ﬂuid total and differential WBCs (CELL-DYN.
ABBOTT, TEXAS, USA.)
- Pleural ﬂuid pH using arterial blood gas machine
;(OMNI-C, ROCH, DIAMOND DIAGNOSTICS
Holliston, MA, USA.)
All patients underwent tube thoracotomyusing large bore chest
tubes (30 French). The patients were assigned to one of the follow-
ing ﬁve groups. Every ﬁfth patient received the same treatment.
The intrapleural injections were done once the pleural ﬂuid output
through the chest tubewas less than150 ml/day.Lidocaine 20 cc of
2% (AstraZeneca, London, UK) was installed intrapleurally 30
minutes before any chemical agent was injected.
Group1: Intrapleural injection of 500 mg of tetracycline
(Pﬁzer, MiddleEast, Cairo, Egypt) mixed with 100 ml of sterile
saline. [8].this low dose of tetracycline was intended to lessen
the pain; it was used before by Wallach [9].
Group2: Intrapleural injection of 5 g of talc (mixed particles,
sized from10–45lm in maximum diameter) (Algomhorya .co.
Ltd, Zagazig, Egypt), in 100 ml of normal saline. The slurry
was made by mixing 5 gm of talc with normal saline and agi-
tated gently [10].
Group3: Intrapleural injection of 20 ml 10% iodopovidone
(NilePharmaceutical Co, 10th Ramadan City, Egypt) mixed
with 80 ml normalsaline [11].
Group4: Intrapleural injection of 1 IU/kg bleomycin (Nip-
pon Kayaku Co., Ltd. Tokyo, Japan), in 100 ml normal saline
[3].
Group5: Chest tube only with no intrapleural injections.
In the ﬁrst four groups whom received chemical agents, the
tube was clamped immediately after injection of the pleurode-
sing solution and remained clamped for 2.5 h. During this time
the patient was turned to the supine, prone, right and left lat-
eral decubitus and sitting positions so that the chemical sub-
stance could come in contact with all pleural surfaces. The
patient was kept in each position for 30 min.
- After 2.5 h, the chest tube was unclamped.
- Follow up chest radiographs were done every 24 h until
the tube was removed.
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- Patients were said to have chest pain if they reported
worse chest discomfort after the intrapleural injection.
The patients had to volunteer that they had most chest
discomfort; they were not asked speciﬁcally about chest
discomfort.
- Patients were said to have fever if their temperature
increased one or more degree Centigrade above what
it had been anytime while they had the chest tube before
the intrapleural injection
- Patients were said to have dyspnea if they complained of
dyspnea at a higher grade than was present before the
procedure;
The tube was removed when the amount of drainage was
<150 cc/24 h in the groups that received the sclerosing agents,
and when the amount of ﬂuid was less than 100 cc/24 h in the
group that received only the chest tube. The smaller amount of
drainage was required in the chest tube only group in order to
increase the likelihood that it would be successful, after dis-
charge the patient was followed by chest X-ray obtained
monthly for the 2 month following pleurodesis.
III- Assessment of the response:
The effectiveness of pleurodesis was evaluated as follows:
[12]
- Complete response (success):
Total resolution of pleural effusion, no recurrence of effu-
sion on the chest X-ray during the period of follow up.
- Failure:
Recurrence of the pleural effusion on the chest X-ray, at
any time during the follow up period.
Statistical methods
The values were presented as mean + SD. For comparison
between groups, analysis of variance (ANOVA) was used
for continuous variables and post hoc test or LSD was used
to ﬁnd signiﬁcant differences between the groups. The chi-
square test was used to compare the groups for the success
rate of pleurodesis and the incidence of side effects. A p-va-
lue <0.05 was considered signiﬁcant. The EPI-INFO (2000)
computer software package was used (WHO version).Table 1 Cancer type distribution among study patients.
Tetracycline N (%) Talc slurry N (%) Iodo
Lung cancer 533.3 426.6 533.3
Lymphoma 533.3 426.6 320.0
Breast cancer 213.3 320.0 320.0
Met.ad.carcinoma 213.3 213.3 213.3
Mesothelioma 16.6 213.3 213.3Results
Of the 75 patients who completed the study, 52 were male and
23 female. The age ranged from 31 to 70 years, the mean ages
were comparable in the study groups. In addition there was no
signiﬁcant difference in the distribution of the tumor types
among the study groups, (Table 1).
That there was no statistically signiﬁcant difference between
groups regarding pleural ﬂuid parameters (WBCs, LDH, pro-
tein concentration, glucose level) (Table 2).
The four sclerosing agents were all effective in producing
pleurodesis. There was no signiﬁcant difference in the effective-
ness of the chemical agents with complete responses occurring
in 67–80% in each group (Table 3), but there was a signiﬁcant
difference between each of the agents and the control group
(chest tube only group).
There was no signiﬁcant difference in the duration of tube
drainage after instillation of the four different chemical agents,
but the group that received only tube thoracostomy had a sig-
niﬁcantly longer period of chest tube drainage. The incidence
of side effects following the intrapleural injection of the scle-
rosing agents were non signiﬁcant, dyspnea was most common
in the talc slurry group occurring in ﬁve of the patients while
chest pain was the most common in the tetracycline group
occurring in ﬁve of the patients. Several patients in each group
developed fever. There were no signiﬁcant differences in the
incidences of any of the three side effects in the groups
(Table 4).
The presence of a positive pleural ﬂuid cytology was an
indicator that the pleurodesis was less likely to be successful.
The positivity of pleural ﬂuid cytology was 34% in successful
patients, which was signiﬁcantly less than that of 88% in the
patients who failed to achieve pleurodesis (Table 5).
Discussion
Our study demonstrates that tetracycline, talc slurry, iodopovi-
done and bleomycin, all resulted in comparable success rates of
80%, 80%, 66.6%, 73.3%, at 30 days and, 66.6%, 73.3%,
60%, 66.6% at 60 days respectively. Tube thoracostomy was
the most inferior, yielding success rates of 40% and 26.7%
at 30 and 60 days respectively. The duration of chest tube
drainage was comparable in the four groups that received a
sclerosing agent, but was longer in the chest tube only group.
Chest pain was more common in the tetracycline group, dysp-
nea was more common in the talc group, and fever was more
common in the iodopovidone group. The effectiveness of
chemical pleurodesis in patients with recurrent, symptomatic






Table 2 WBCs, LDH, protein and glucose in the pleural ﬂuid among studied patients.
Tetracycline Talc slurry Iodopovidone Bleomycin Tube alone P
WBC Cells/mm3 698 ± 137 683 ± 196 644 ± 151 699 ± 186 594 ± 184 0.41
LDH. IU/L 1710 ± 546 1810 ± 248 1890 ± 395 1860 ± 395 1410. ± 475 0.26
Glucose mg/dl 70 ± 20 72 ± 14 79 ± 11 79 ± 12 76 ± 11 0.26
Protein. gm/dl 4.4 ± 0.6 4.5 ± 0.5 4.2 ± 0.5 4.2 + 0.3 3.8 ± 0.5 0.56
pH 7.32 ± .06 7.33 ± .04 7.28 ± .06 7.29 ± .06 7.33 ± .08 0.33
Table 4 Complications encountered due to pleurodesis in different study groups.
Tetracycline Talc slurry Iodopovidone Bleomycin Tube only P
No (%) No (%) No (%) No (%) No (%)
Dyspnea 2 13% 5 33.3% 1 6.5% 1 6.5 1 6.5% 0.14
Chest pain 5 33.3% 4 26% 2 13% 4 26% 1 6.5% 0.36
Fever 2 13% 4 26% 5 33% 4 26% 2 13% 0.63
Table 3 Success rate of different pleurodesis methods among studied patients.
Tetracycline
(n= 15) NO. %
Talc slurry
(n= 15) NO. %
Iodopovidone
(n= 15) NO. %
Bleomycin
(n= 15) NO. %




12 (80) 12 (80) 10 (66.7) 11 (73.3) 7.60.1 6 (40)
Success rate
at 60 days
10 (66.7) 11 (73) 9 (60.0) 10 (66.7) 8.47 07 4 (26.7)
Table 5 Effect of positive pleural ﬂuid cytology on pleurod-
esis success in different patients group.
Positive PF cytology
in success group No (%)
Positive PF cytologyin
failed group No (%)
p
Tetracycline 5/12 (41%) 3/3 (100%) 0.024
Talcslurry 4/12 (33.3%) 3/3 (100%) 0.035
Iodopovidone 3/10 (30%) 4/5 (80%) 0.032
Bleomycin 2/6 (33.3%) 8/9 (88.8%) 0.023
Tubeonly 3/10 (30%) 4/5 (80%) 0.032
TOTAL 17/50 (34%) 22/25 (88%) 0.02
118 W. Shouman et al.studies. However, there is still much debate about which agent
is best. It is very difﬁcult to compare the effectiveness of these
agents between studies because different studies used varying
doses of the sclerosing agents and different techniques for
pleurodesis (tube size, duration for tube thoracostomy before
and after the injection of the sclerosant and varying criteria
for success) [13].
Currently, talc either in sufﬂation or as slurry, tetracycline
derivatives, mitoxantrone, bleomycin, silver nitrate and iodop-
ovidone are the most commonly used sclerosing agents [5]. The
goal of our current study was to compare the effectiveness of
four of these agents in which the same pleurodesis procedure
was used.
Talc was the ﬁrst agent to be used for pleurodesis. In 1935
Bethune instilled talc intrapleurally in an attempt to create
pleural adhesions after a lobectomy [14].In a survey of pleu-
rodesis practices among English speaking pulmonologists in
2003, talc was the agent most commonly used [5]. Talc is com-
monly used because it is inexpensive, widely available and per-
ceived to be very effective. However, in the largest study ever
done with pleurodesis, talc either insufﬂated or administered
as slurry was not particularly effective [5]. In this prospective,
randomized trial [6], with 482 patients reported by Dresler
et al. [6], the success rate with insufﬂated talc administered
at thoracoscopy was comparable with that of talc slurry [6],
The success rates at 30 days with insufﬂated talc was (78%)
and for talc slurry was (71%), which did not differ signiﬁcantly
[6]. Most troublesome was the signiﬁcant mortality when talc
was administered in either manner. Treatment-related mortal-
ity occurred in nine (3.7%) of patients receiving talc insufﬂa-
tion and seven (2.9%) patients receiving talc slurry.
Respiratory complications were more common following talc
insufﬂation than talc slurry (14% vs. 6%). Respiratory failurewas observed in 4% of talc slurry patients and 8% of talc
insufﬂation patients. Other studies with talc have reported
higher success rates, Haddad et al. [15] reported a success rate
of 85% for 71 patients treated with 4 gm talc slurry. Adler and
Sayek [16] reported a success rate of 93% in 41 patients treated
with 10 gm of talc. In the current study, the success rates of
talc slurry were 80% after 30 days and 73.3% after 60 days,
which are comparable to the results of Haddad et al. [15]
and Dresler et al. [6]. But it was lower than that reported by
Adler and Sayek, a possible explanation for the higher success
ratesreported by Adler and Sayek is that, they used a higher
dose of talc (10 gm) [16].
In the talc slurry group, the most common side effect was
dyspnea which occurred in 33.3%. However, none of our pa-
tients developed ARDS.
Tetracycline and its derivatives were the second most com-
monly used agent for chemical pleurodesis in the survey of
pleurodesis practices among English speaking pulmonologists
in 2003. In this survey, who used tetracycline or its derivatives
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ported that tetracycline in a dose of 1,500 mg, effectively con-
trolled malignant pleural effusion in 94.4% of 108malignant
pleural effusions at 30 days. Another study reported that, pleu-
rodesis was achieved with 500 mg tetracycline in (67%) of
356patients [9]. In the current study tetracycline achieved pleu-
rodesis in 80% of patients at 30 days and in 66.7% at 60 days.
Our results were consistent with the results reported by Wal-
lach [9], but were less than those reported by Sherman et al.
[17], possibly because of the high dose of tetracycline
1500 mg used in Sherman study compared to 500 mg used in
our study. The most common side effect for Tetracycline in
most studies has been chest pain. The intrapleural administra-
tion of tetracycline in patients with spontaneous pneumotho-
rax was associated with intense chest pain in many patients
[18]. In our study, tetracycline caused chest pain in 33%, dysp-
nea in 13% and fever in 13% of patients. A possible reason
that patients in present study did not have more pain is that
they received Lidocaine 2% intrapleurally and the dose of tet-
racycline was lower (500 mg).
Bleomycin was the third most commonly used agent for cre-
ating pleurodesis in the survey of pleurodesis practices among
English speaking pulmonologists in 2003. In this survey, phy-
sicians who used bleomycin reported success rates of
62 ± 16% [5]. The popularity of bleomycin is due in part to
the randomized controlled study by Ruckdeschel et al. [19]
who compared 60 units of bleomycin and 1000 mg of tetracy-
cline in 44 patients. In this study the success rate with bleomy-
cin at 30 days (64%) was signiﬁcantly (p= 0.023) higher than
that with tetracycline (33%) [19]. in a review of 199 patients
treated with bleomycin for malignant pleural effusion, a com-
plete response was achieved in 54% (108 patients) [20]. Subse-
quently, Diacon et al. [21], in a prospective, randomized
comparison of bleomycin and talc slurry in 36patients reported
that the complete response rate with bleomycin (59%) was
insigniﬁcantly (p= 0.12) less than that for talc (87%) [21].In
the current study bleomycin achieved pleurodesis in 73.3%
of patients at 30 days and in 66.6% at 60 days, the response
rates to bleomycin in the current study tended to be slightly
higher than those reported in the literature.
Although the general concept is that bleomycin is less effec-
tive than talc or tetracycline derivatives in producing pleurod-
esis [15], in the current study bleomycin achieved a success rate
comparable to both talc and tetracycline.
The disadvantages of bleomycin are its higher cost, com-
pared with talc and tetracycline, but not a lower success rate
at least in the present study. Few studies had compared the
three agents, but in the survey of Lee et al. [5] comparing the
perceived success rates of the most commonly used agents
for creating pleurodesis, physicians who used talc poudrage re-
ported a signiﬁcantly higher success rate (73 ± 17%) of pleu-
rodesis than those used talc slurry (68 ± 17%), tetracycline
and its derivatives (61 ± 19%), and bleomycin (62 ± 16%).
Those who used talc slurry in turn reported a higher success
rate than tetracycline derivatives and bleomycin [5].
Iodopovidone is a topical antiseptic which has been shown
to be safe and effective when used for pleurodesis in several
series, including multicenter studies [22–24]. Olivares et al.
[24] reported that iodopovidone is an effective, safe, readily
available, and inexpensive alternative to achieve chemical pleu-
rodesis in cases of recurrent, incapacitating effusions, regard-
less of etiology. In the prospective multicenter study ofOlivares and coworkers [24] 100 ml of 2% iodopovidone was
instilled intrapleurally in 52 patients. In this study a complete
response (no reaccumulation of the ﬂuid during the follow-up),
was obtained in 50 patients (96.1%). Echavarria et al. [22]re-
ported a complete response in all 15 patients with malignant
pleural effusion who underwent pleurodesis with iodopovi-
done. The efﬁcacy of iodopovidone in a prospective study by
Ritech et al. [25] in which pleurodesis was performed with
iodopovidone 2% solution infused through a chest tube and
left in the pleural cavity for 4 h. was86.5% [25]. In another
study by Garcia et al. [26], successful pleurodes is was achieved
in 9 of 14 patients (64.2%) by iodopovidone through tube tho-
racostomy [26].
In the current study, the success rate of iodopovidone 2%
was 66.7% at 30 days and 60% at 60 days which did not differ
signiﬁcantly from the other agents (tetracycline, talc slurry,
bleomycin). Our results were similar with those of Garcia
et al. [26], but lower than those of Olivares et al. [24] possibly
because thoracoscopy was used in most patients in the latter
study. Our results were also inconsistent with Ritech et al.
(86.5%) [25], It should be noted that in this study of Ritech
et al. [25], the solution was left in the pleural cavity for a long
period (4 h), and the 64 patents included in this study 37 of
them had malignant pleural effusion and 27 had pneumotho-
rax, this may explain the higher success rate in this study
[25], compared to our success rate (66.7%).The reported side
effects of iodobovidone in our study were dyspnea 6.5%, chest
pain 13% and fever33%.
An interesting ﬁnding in our study was that most of patients
who failed to achieve pleurodesis had positive pleural ﬂuid
cytology for malignancy 22 of 25 (88%), while only 17 of 50
(34%) with successful pleurodesis had positive cytology. We
hypothesize that the lower rate of pleurodesis inpatients with
positive cytology is due to the fact that they have a larger tumor
burden which covers a higher percentage of the pleural surfaces.
Accordingly, the mesothelial cells are covered with the tumor
and cannot respond to the pleurodesis agents in the usual
manner.
Conclusion
Chemical pleurodesis is a widely accepted method of treatment
for recurrent symptomatic malignant pleural effusions. The
agent of choice should be safe, easy to apply, readily available,
inexpensive, and associated with a high rate of success. Since in
this study comparing talc slurry, tetracycline, iodopovidone,
and bleomycin no agent was signiﬁcantly better than the others,
we suggest that economic costs, drug availability and medical
skill should be considered in the choice of a sclerosing agent.
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